Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Autor: Brian A. Bergmark, Nicholas A. Marston, Candace R. Bramson, Madelyn Curto, Vesper Ramos, Alexandra Jevne, Julia F. Kuder, Jeong-Gun Park, Sabina A. Murphy, Subodh Verma, Wojtek Wojakowski, Steven G. Terra, Marc S. Sabatine, Stephen D. Wiviott, Diane Carbonneau, Raphael Poulin-Robitaille, Jeffrey Wayne, Keung Lee, Samuel Mujica Trenche, Petros Dzongowski, Daniel Gaudet, Joanna Van, Dilawar Ajani, Harold Bays, John O’Mahony, Adam Janas, John Scott, Moustafa Ashraf Moustafa, Thomas Ransom, Sabrina Benjamin, Naresh Aggarwal, Pawel Bogdanski, Douglas Friars, Robert Schlosser, Boguslaw Okopien, Madhusudan Budhraja, Lawrence Feld, Leslie Klaff, Guy Tellier, Giuseppe Mazza, Iwona Wierzbicka, Ewa Jazwinska-Tarnawska, Fernando Boccalandro, Julio Rosenstock, Elizabeth Marquez, Kim Barbel-Johnson, Katarzyna Madziarska, Kenneth Heaton, Jean-Claude Tardif, John Rubino, Miguel Trevino, Katie Moriarty, Anil Gupta, Wojciech Wojakowski, James Fidelholtz, Dinesh Gupta, Hani Alasaad, Shane Christensen, Parag Shah, Stephanie Li, Mark Sherman, Andre Frechette, Cecilia Arango, Alan Egan, Sunny Srivastava, Archna Bajaj, Carlos Ince Jr, Aleksander Zurakowski

Publikováno v: Circulation. 145(18)

Background: Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Methods: Adults

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a6c0c8169d6edb06e1e63884560053
https://pubmed.ncbi.nlm.nih.gov/35449408